Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.27 -0.10 (-0.21%)

Streaming Delayed Price Updated: 10:14 AM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

February 22, 2025

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes ↗

February 18, 2025

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Via Benzinga

How Is The Market Feeling About Sanofi? ↗

February 14, 2025

Via Benzinga

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study ↗

February 13, 2025

Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge.

Via Benzinga

How Is The Market Feeling About Sanofi? ↗

January 24, 2025

Via Benzinga

Price Over Earnings Overview: Sanofi ↗

January 10, 2025

Via Benzinga

How Is The Market Feeling About Sanofi? ↗

December 30, 2024

Via Benzinga

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. ↗

February 06, 2025

The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.

Via Investor's Business Daily

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday ↗

February 04, 2025

Via The Motley Fool

Sanofi Buys Back ~$3 Billion In Shares From L'Oréal: Details ↗

February 03, 2025

Sanofi has purchased 2.3% of its shares from L'Oréal SA as part of its share repurchase program. The €3 billion deal involves acquiring 29.6 million shares at €101.50 each, with cancellation expected...

Via Benzinga

Sanofi (SNY) Q4 2024 Earnings Call Transcript ↗

January 30, 2025

SNY earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data ↗

January 28, 2025

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD.

Via Benzinga

A Look Into Sanofi Inc's Price Over Earnings ↗

December 25, 2024

Via Benzinga

Why NASDAQ:SNY qualifies as a good dividend investing stock. ↗

December 16, 2024

Balancing Dividends and Fundamentals: The Case of SANOFI-ADR (NASDAQ:SNY).

Via Chartmill

Earnings Scheduled For January 30, 2025 ↗

January 30, 2025

Via Benzinga

Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm? ↗

January 28, 2025

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald...

Via Benzinga

Topics Government

Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses ↗

January 22, 2025

FDA issues warning letter to Sanofi over its Genzyme facility, citing process deviations, equipment issues, and quality oversight lapses.

Via Benzinga

AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion ↗

January 18, 2025

Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,...

Via Talk Markets

Topics Artificial Intelligence Stocks / Equities

Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week ↗

January 16, 2025

The company is working to launch its COPD treatment more broadly. The drug is a non-steroidal nebulizer.

Via Investor's Business Daily

Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma ↗

January 09, 2025

Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.

Via Benzinga

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies ↗

January 08, 2025

Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.

Via Benzinga

Topics ETFs

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? ↗

December 22, 2024

The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio?

Via Benzinga

Why Cytokinetics Stock Was a Nearly 5% Winner Today ↗

December 20, 2024

Via The Motley Fool

In a market where value is scarce, NASDAQ:SNY offers a refreshing opportunity with its solid fundamentals. ↗

December 20, 2024

When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases ↗

December 18, 2024

Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets.

Via Benzinga

RCI Hospitality, Quantum Computing, Teva Pharmaceutical, Tesla And Other Big Stocks Moving Higher On Monday ↗

December 17, 2024

Via Benzinga

Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug ↗

December 17, 2024

Teva and Sanofi are partnered on a drug to treat inflammatory bowel disease. The drug showed "best-in-class potential" in midstage testing.

Via Investor's Business Daily

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? ↗

December 17, 2024

Teva and Sanofi's Phase 2b RELIEVE UCCD study shows duvakitug improves remission in ulcerative colitis and response in Crohn's disease.

Via Benzinga

Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation ↗

December 17, 2024

HRSA warns Sanofi that its credit model for 340B drugs violates the statute, demanding immediate cessation to avoid penalties and pricing agreement termination.

Via Benzinga

Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children ↗

December 13, 2024

Lawyer files petition against polio vaccine, part of broader anti-vaccine campaign by Robert F. Kennedy Jr. and Aaron Siri, causing concerns for vaccine policies and pharma companies. Trump considering...

Via Benzinga

Topics Government

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.